Oral Teriflunomide study shows lasting efficacy and safety
Oral Teriflunomide study shows lasting efficacy and safety
The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.
The findings came from open-label extensions of phase II and III studies with teriflunomide, which is now under FDA review as a treatment for relapsing-remitting MS. The results were presented in a series of posters at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2030 Views
-
Last post by NHE
-
- 0 Replies
- 1310 Views
-
Last post by frodo
-
- 0 Replies
- 970 Views
-
Last post by frodo
-
- 0 Replies
- 9995 Views
-
Last post by NHE
-
- 0 Replies
- 1680 Views
-
Last post by Tif
-
- 1 Replies
- 1084 Views
-
Last post by Petr75
-
- 0 Replies
- 1790 Views
-
Last post by DIM
-
- 0 Replies
- 1946 Views
-
Last post by DIM
-
- 0 Replies
- 1545 Views
-
Last post by frodo